Amazon announced on Friday that its digital pharmacy will begin offering Novo Nordisk’s newly launched oral version of Wegovy in the United States, joining more than 70,000 retail pharmacies and several telehealth providers. Novo Nordisk began rolling out the pill in the U.S. earlier in the week, with a cash starting dose of $149 per month and insured patients able to pay as little as $25 a month. Amazon said it will add the pill to prescription vending kiosks in select One Medical clinics in the coming weeks while leveraging its same‑day delivery network and price‑transparency features. The move underscores an industry shift as oral GLP‑1/Tirzepatide‑class therapies enter a market long dominated by weekly injections.
Key Takeaways
- Amazon Pharmacy announced Friday it will dispense Novo Nordisk’s oral Wegovy pill in the U.S.; the launch follows Novo Nordisk’s rollout earlier this week.
- The manufacturer lists a starting cash price of $149 per month for the oral Wegovy dose; insured customers may pay as little as $25 for a one‑month supply via certain plans.
- Wegovy’s pill is already available at more than 70,000 U.S. pharmacies, including CVS and Costco, and through telehealth platforms such as Ro, LifeMD, WeightWatchers and GoodRx.
- Amazon plans to add the pill to prescription vending kiosks at select One Medical clinics and offers same‑day prescription delivery to nearly half of U.S. consumers, per the company.
- Amazon Pharmacy originated from Amazon’s 2018 PillPack acquisition (~$750 million) and expanded after the 2022 One Medical purchase ($3.9 billion), part of a broader push into health care.
- Analysts have estimated Amazon Pharmacy could generate roughly $2 billion in annual revenue, though Amazon has not disclosed user counts.
- The oral option is expected by experts to lower barriers for patients who avoid injections and broaden access to obesity treatment.
Background
Wegovy is Novo Nordisk’s brand of semaglutide originally approved and distributed as a weekly injection for chronic weight management; the company has now introduced an oral formulation in the U.S. The injectable GLP‑1 class — and rival drugs such as Eli Lilly’s tirzepatide formulations — have dominated headlines and prescriptions, driving rapid growth in obesity and diabetes therapeutics. Novo Nordisk’s decision to offer a pill follows a broader industry trend of expanding distribution channels beyond specialty clinics and retail pharmacies to include direct‑to‑consumer and telehealth partners.
Amazon Pharmacy launched in 2020 after Amazon acquired PillPack in 2018 and later added primary‑care assets such as One Medical in 2022, signaling a multi‑front strategy in U.S. health care. The company promotes speed (same‑day delivery to a large share of U.S. households) and transparent pricing as competitive advantages. Drugmakers and digital health firms have recently formed distribution partnerships with Amazon Pharmacy; these alliances reflect manufacturers’ efforts to reach patients through nontraditional retail and online routes.
Main Event
On Friday, Amazon said eligible customers with insurance can obtain a one‑month supply of the Wegovy pill for as little as $25, while cash‑pay options will begin at $149 per month. Amazon will make the medication available through its existing prescription fulfillment channels and said that, in the coming weeks, vending kiosks in select One Medical locations will carry the pill. The company has emphasized delivery speed and price transparency as customer benefits tied to the new listing.
The oral Wegovy launch this week also saw rollout across more than 70,000 U.S. pharmacies — including major chains — and distribution via telehealth platforms and pharmacy partners such as NovoCare Pharmacy. WeightWatchers announced an October partnership with Amazon Pharmacy to distribute weight‑loss medications for its membership, and Amazon has previously worked with Eli Lilly on fulfillment for select prescription medications, including Zepbound.
The market context includes direct‑to‑consumer sales arrangements: the same starting dose will be offered for $149 per month on the TrumpRx website under a deal Novo Nordisk struck with the administration in November, with that site slated to launch in January though exact timing remains unclear. Meanwhile, rival oral and injectable obesity treatments from other manufacturers are advancing through regulatory and commercial stages, intensifying competition.
Analysis & Implications
The addition of Wegovy’s oral pill to Amazon Pharmacy amplifies distribution reach by coupling a national e‑commerce and delivery network with established pharmacy footprints. For patients, pharmacy and telehealth availability plus an oral formulation can reduce traditional barriers — needle aversion, clinic appointment logistics and limited specialty‑care access — that previously constrained uptake of injectable therapies. Insurers’ copay structures and manufacturer assistance programs will still shape out‑of‑pocket costs for many patients.
For Novo Nordisk, placing the pill on Amazon and across broad retail channels signals a deliberate strategy to diversify access points beyond specialty clinics and to accelerate market penetration. The company benefits from near‑ubiquitous retail presence while retaining pricing tiers for cash and insured patients. Competitors such as Eli Lilly are advancing rival oral and injectable products, so distribution scale and pricing will be central battlegrounds.
Amazon gains strategic value by listing a high‑demand obesity medication: it can drive pharmacy traffic, deepen consumer engagement with health services and leverage logistics to differentiate on convenience. However, the company faces operational and regulatory scrutiny around pharmacy accuracy, controlled distribution, and the risks of scaling complex drug fulfillment nationwide. Insurer negotiations and state pharmacy rules could influence how broadly the pill becomes available through Amazon’s channels.
Comparison & Data
| Product / Channel | Starting cash price | Insured price (reported) | Availability |
|---|---|---|---|
| Wegovy (oral pill) | $149 / month | As low as $25 / month | Amazon Pharmacy, 70,000+ U.S. pharmacies, telehealth partners |
| Wegovy (injectable) | — (varies by plan/retailer) | Varies by insurer | Specialty clinics, retail pharmacies |
The table summarizes manufacturer‑stated starting cash pricing for the oral Wegovy dose and reported insured costs; injectable pricing varies widely by plan and pharmacy. The oral formulation’s relatively low cash entry price places it among the more accessible options in a market otherwise characterized by high list prices for some weekly injectables. Future public pricing comparisons will depend on insurer formularies, manufacturer coupons and patient assistance programs.
Reactions & Quotes
Several stakeholders responded to the rollout and Amazon listing with brief statements or industry commentary that reflect differing priorities: access, competition and logistics.
“Eligible customers with insurance can pay as little as $25 for a one‑month supply,” Amazon said, highlighting the lower insured out‑of‑pocket option for some patients.
Amazon (company statement)
“An oral option could expand access to people who avoid injections, making obesity treatment more approachable for new patient groups,” a public‑health clinician said, noting potential increases in demand.
Independent public‑health clinician (expert comment)
“We are broadening distribution to reach patients beyond traditional specialty channels,” Novo Nordisk said in describing its multi‑channel rollout strategy.
Novo Nordisk (company statement)
Unconfirmed
- The total number of Amazon Pharmacy users has not been publicly disclosed; analyst revenue estimates (~$2 billion) are projections, not company figures.
- The exact national rollout timeline for vending kiosks in all One Medical clinics is not specified beyond “coming weeks.”
- Specific launch dates and inventory details for Wegovy on third‑party sites such as TrumpRx remain unclear pending those services’ public schedules.
Bottom Line
Amazon Pharmacy’s decision to list Novo Nordisk’s oral Wegovy pill widens distribution and could lower nonfinancial barriers to obesity treatment by offering a daily pill via fast delivery and broad retail access. The cash price entry at $149 and insured copays reported as low as $25 make the pill competitively priced at launch, but real affordability will depend on insurer formulary decisions and assistance programs.
For the health‑care market, the move intensifies competition among manufacturers and distributors as oral obesity therapies scale. Observers should watch insurer coverage rules, pharmacy supply logistics and real‑world uptake data to assess whether broader availability translates into sustained increases in treatment access and clinical outcomes.